Ionis Pharmaceuticals, Inc.
IONS
$72.33
-$0.01-0.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.26% | 17.12% | 100.69% | 10.14% | -30.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.26% | 17.12% | 100.69% | 10.14% | -30.18% |
| Cost of Revenue | 15.35% | -0.34% | -2.04% | -6.54% | -3.97% |
| Gross Profit | -270.53% | 27.17% | 23,662.17% | 27.11% | -135.05% |
| SG&A Expenses | 47.81% | 57.06% | 39.18% | 44.84% | 72.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.83% | 12.19% | 7.17% | 3.52% | 8.62% |
| Operating Income | -93.51% | -7.75% | 311.55% | 1.77% | -898.61% |
| Income Before Tax | -112.93% | 10.90% | 286.60% | -2.87% | -3,768.41% |
| Income Tax Expenses | 154.94% | 105.88% | -131.25% | 54.67% | -141.41% |
| Earnings from Continuing Operations | -119.83% | 8.45% | 286.45% | -2.90% | -1,026.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -119.83% | 8.45% | 286.45% | -2.90% | -1,026.51% |
| EBIT | -93.51% | -7.75% | 311.55% | 1.77% | -898.61% |
| EBITDA | -94.74% | -7.98% | 326.46% | 1.56% | -733.19% |
| EPS Basic | -114.42% | 14.85% | 271.01% | 5.66% | -927.06% |
| Normalized Basic EPS | -113.48% | -1.56% | 307.64% | 8.57% | -642.39% |
| EPS Diluted | -114.42% | 14.85% | 254.19% | 5.66% | -927.06% |
| Normalized Diluted EPS | -113.48% | -1.56% | 281.22% | 8.57% | -642.39% |
| Average Basic Shares Outstanding | 2.53% | 7.52% | 9.03% | 9.07% | 9.72% |
| Average Diluted Shares Outstanding | 2.53% | 7.52% | 24.92% | 9.07% | 9.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |